According to a previous study [24], lncRNA cancer susceptibility candidate 2 (CASC2) could modulate glioma growth and resistance to Temozolomide through phosphatase and tensin homolog (PTEN) pathway by targeting miR-181a. The gene discussed is CASC2; the disease is glioma.